acf/google-ad-placement

<ul>
	<li>A federal judge dismissed a whistleblower lawsuit accusing&nbsp;Novartis AG&nbsp;NVS of paying doctors kickbacks at &quot;sham&quot; speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya.</li>
	<li>U.S. District Judge Kimba Wood dismissed the whistleblower lawsuit, arguing that former Novartis sales representative Steven Camburn did not provide enough detail to support his claims.</li>
	<li>Camburn&#39;s lawyer says he and his client plan to appeal the decision, adding that they&#39;re confident the ruling will be reversed,&nbsp;<a class="editor-rtfLink" href="https://www.reuters.com/legal/government/novartis-escapes-claim-that-it-paid-kickbacks-promote-ms-drug-2022-09-13/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Reuters reports</a>.&nbsp;</li>
	<li>Gilenya was the company&#39;s third-best-selling drug in 2021,&nbsp;<a class="editor-rtfLink" href="https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2021.pdf" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">bringing in $2.8 billion worldwide</a>&nbsp;out of $51.6 billion in total sales.</li>
	<li>Camburn sued Novartis in 2013 under the False Claims Act, claiming that Novartis paid doctors up to $3,500 to participate as speakers in purportedly educational speaker events to induce them to prescribe and promote Gilenya.</li>
	<li>Novartis, in 2020, agreed to pay $729 million to settle similar whistleblower claims related to its speaker program and its diabetes and cardiovascular drugs.</li>
	<li>Price Action:&nbsp;NVS shares are down 1.55% at $80.68 on the last check Wednesday.</li>
	<li>Photo via Wikimedia Commons</li>
</ul>

Biotech

Large Cap

News

Health Care

Legal

General

 A federal judge dismissed a whistleblower lawsuit accusing&nbsp;Novartis AG&nbsp;(NYSE: NVS) of paying doctors kickbacks at &quot;sham&quot; speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya. 

Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims - Novartis (NYSE:NVS)

Vandana Singh

Novartis

<ul>
	<li>A federal judge dismissed a whistleblower lawsuit accusing&nbsp;Novartis AG&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) of paying doctors kickbacks at &quot;sham&quot; speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya.</li>

Briefs

Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims

Novartis AG

Application error: a client-side exception has occurred (see the browser console for more information).